Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Riferminogene pecaplasmide (Primary)
- Indications Peripheral arterial disorders
- Focus Therapeutic Use
- Acronyms TALISMAN 201
- Sponsors Sanofi
- 04 Jun 2014 New trial record